Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 4.97%

Arrowhead Pharmaceuticals reported a loss that was greater than expected, leading to a stock decline of nearly 5%. Investors may be concerned about the company's financial performance, especially since no revenue figures were provided. The lack of guidance and commentary from management adds uncertainty about future prospects.